BriaCell Therapeutics Corp.
Most recent annual filing: 2025-10-16
Pipeline (8 active programs)
Bria-OTS
Bria-BRESBria-PROS+
Bria-LUNG+
Bria-MEL+
Bria-BRES+
Soluble CD80
sCD80- Undisclosed indication
Soluble CD80
sCD80 · BP-80- Undisclosed indication
Technology platforms
TILsRx
Proprietary platform designed to activate tumor-infiltrating lymphocytes (TILs) within the tumor microenvironment; integrates T cell engagers and immune checkpoint modulators; multivalent technology enables simultaneous engagement of multiple cancer-associated and immune pathway targets; focus areas include prostate, lung, breast, pancreatic, and ovarian cancers; early agents include antibodies to B7-H3
Targets: B7-H3
Bria-TILsRx
Quadrivalent multi-specific binding reagents designed as potent immune cell activators and/or immune checkpoint inhibitors; selectively target and destroy cancer cells while minimizing effects on normal cells; focus on immuno-oncology across multiple cancer types
Targets: B7-H3
Biotech Distilled coverage (5)
- 2026-03-15 UPDATE: BriaCell (BCTX) – The War Chest is Full and AACR is on Deck 🔒 Paid
- 2026-02-21 UPDATE: BriaCell (BCTX) – A Safety Nod and a Corporate Shell Game 🔒 Paid
- 2026-01-31 UPDATE: BriaCell (BCTX) Drops the Receipts on Super Responders 🔒 Paid
- 2026-01-14 UPDATE: BriaCell (BCTX) Just Gave Us a Masterclass in Pump and Raise 🔒 Paid
- 2026-01-09 BriaCell (BCTX): Scientific Deep Dive for Bria-IMT™ and Pipeline Products 🔒 Paid
Articles open on Substack. Some deep dives are subscriber-only.